ISID Knowledge Exchange & E-Learning Platform (IKEEP)

ISID Knowledge Exchange &

E-Learning Platform (IKEEP)

ISID Knowledge Exchange & E-Learning Platform (IKEEP)

The ISID Knowledge Exchange & E-Learning (IKEEP) is an online resource that shares open-access educational modules, webinars, and interactive discussions. ISID’s new online learning environment focuses on sharing evidence-based information for infectious disease management, control and prevention in resource-limited settings.

The content hosted on IKEEP serves as an enduring resource for practitioners around the globe with a focus on low- and middle-income countries. Launched in October 2020, IKEEP regularly shares critical infectious disease knowledge covering a range of global infectious disease priorities and provides content focused on career development and leadership skill-building.


Join the IKEEP Mailing List

Coming Soon to IKEEP


    • Dr. Ann Falsey, Professor of Medicine, University of Rochester School of Medicine, New York, USA
      • The Global Burden of Influenza Morbidity and Mortality
    • Prof. Bruno Lina, Professor of Virology, Lyon, France
      • The Impact of COVID-19 on Influenza Surveillance and Transmission 
    • Prof. Zamberi Sekawi, ISID Executive Committee Member, Malaysia
      • The Impact of Influenza Vaccines on Public Health


    • Prof. Patricio Acosta, Hospital de Niños Ricardo Gutiérrez - CONICET, Argentina
    • Dr. Therese Umuhoza, ProMED Moderator, Rwanda


WHO estimates that seasonal influenza may result in 290,000 – 650,000 deaths each year due to respiratory diseases alone. This estimate does not take into account deaths from other diseases such as cardiovascular disease, which can be influenza-related. Surveillance and laboratory studies of all influenza-related diseases are ongoing and are expected to reveal substantially higher estimates of disease burden. Webinar attendees will engage with experts who will provide updates on global influenza surveillance efforts and estimated burden of disease. They will discuss the importance of country-level influenza estimates to inform national and global preparedness, prevention and control efforts and will highlight remaining gaps. The clinical, social, and economic advances gained from expanded access and uptake of influenza vaccines will be addressed and the lack of reliable data on the possible impact of vaccination among specific high-risk groups will be highlighted.  

The full impact of COVID-19 and nonpharmaceutical interventions on seasonal influenza remains to be determined. Experts will discuss questions around the impact of COVID-19 on influenza surveillance, the role of genomic sequencing for influenza surveillance as a way to better understand disease spread and improve prevention efforts and what to expect during the next influenza season.

*This webinar is supported by an Unrestricted Educational Grant from Sanofi Pasteur.

Add to your Google Calendar

Add to your Apple/Outlook/Office 365 Calendar

Other Upcoming Topics:

  • AMR Surveillance
  • Antifungal Stewardship
  • Dengue

Available Content on IKEEP


    • Dr. Brenda Kwambana-Adams, Research Associate, Division of Infection & Immunity, University College, London, United Kingdom
      • Equitable and Sustainable Access to Meningococcal Vaccines
    • Prof. Marco A. Safadi, Head, Department of Pediatrics, Santa Casa de São Paulo, Brazil
      • Atypical Presentations and the Impact of COVID-19


    • Prof. Rob Heyderman, ISID Executive Committee Member, UK
    • Dr. Christina Obiero, ISID Emerging Leader, Kenya


Meningococcal meningitis is a devastating disease with high mortality and long-term sequelae even in successfully managed cases. Although the burden of disease is greatest in the meningitis belt of sub-Saharan Africa, meningitis is a world-wide threat. Recent epidemics in Liberia, Nigeria, Togo, Niger, Guinea, Kyrgyzstan, Fiji and Chile and the spread of some virulent strains across the world has emphasized the need for a global approach to surveillance and prevention.

In this session, experts will discuss the urgent need for improved monitoring of invasive meningococcal disease and sequelae globally, will discuss the use of whole genome sequencing, strain typing and rapid diagnostics to better understand outbreak epidemiology and burden of disease and will provide updates on the emergence of new clones and hypervirulent strains. They will review WHO’s recently released Defeating Meningitis by 2030 Global Roadmap and what it will take to make vaccines widely available in low- and middle-income countries.

The clinical presentations of meningococcal disease can vary. Recent observations suggest that certain serogroups may present with atypical signs and symptoms such as acute gastrointestinal symptoms, septic arthritis, bacteremic pneumonia or severe upper respiratory infection. Experts will discuss atypical clinical presentations which can be associated with higher case fatality rates and misdiagnoses. The immediate and longer-term impact of COVID-19 on meningococcal disease and meningococcal vaccine schedules is currently unclear and needs to be determined.

*This webinar is supported by an Unrestricted Educational Grant from Sanofi Pasteur.

Watch Here

Speakers: Assistant Prof. Michelle Doll, Prof. Shaheen Mehtar, Prof. Ziad Memish, Prof. Victor Rosenthal, Prof. Mike Stevens, Prof. Sade Ogunsola

Moderator: Prof. Gonzalo Bearman

Abstract: The ongoing COVID-19 pandemic has highlighted both challenges and opportunities for infection control practices at healthcare facilities around the globe. In this moderated discussion, infection prevention and control experts will describe how they responded to the pandemic and what they did to quickly adapt existing helathcare protocols. Speakers will describe how these approaches and the lessons learned from the COVID-19 pandemic can help us better prepare for future outbreaks. Questions addressed during this webinar will include: Will the re-use of presonal protective equipment become standard practice in the future? What can we experct in terms of face mask requirements over the next few years? How can surveillance, reporting and laboratory structures established during the pandemic be maintained in the future?

Watch Here

Speaker: Dr. Terry Schraeder

Abstract: Physicians and healthcare leaders may have many important opportunities to give public speeches and presentations as well as engage with traditional and digital media throughout their careers. Speaking to live audiences, giving online video presentations, answering questions at press conferences and being interviewed by journalists are just a few examples. Learning how to be confident, clear, calm, concise, and engaging in front of an audience, as well as honing the message and improving specific communication skills in a variety of settings are imperative to help optimize a speaker’s message and mission. 

Watch Here

Speaker: Prof. Shabir Madhi, University of Witwatersrand, South Africa

Moderator: Prof. Neelika Malavige, ISID Executive Committee Member, Sri Lanka

Abstract: The emergence and spread of COVID-19 variants raises new questions and scientists must debate whether the variants undercut the effectiveness of first-generation COVID-19 vaccines. The new strains of SARS-CoV-2, first identified in the United Kingdom (B.1.1.7), Brazil (P.1) and South Africa (B.1.351), have developed a substantial number of mutations, especially in the S-protein, that seem to reduce the effects of antibodies crucial to fending off infection. This webinar is a follow up to ISID’s webinar on “COVID-19 Vaccinology Update: Development, Use and Effect on Public Health” released in January 2021. Prof. Malavige and Prof. Madhi will discuss the implications of these mutations on vaccine response and how vaccine manufacturers plan to update their vaccines to better target the emerging variants. Additionally, Prof. Madhi will discuss new results from phase 3 trials and what it will take to achieve herd immunity.

Watch Here

Speaker: Prof. Lisa Ng, Singapore Immunology Network A*STAR, Singapore

Moderator: Prof. Robert Heyderman, ISID Executive Committee Member, United Kingdom

The exact duration of immunity induced by natural COVID-19 infection of the newly produced COVID-19 vaccines is still unclear. Natural infection and coronavirus vaccines induce both humoral (antibody-induced) and cellular immune responses and both are important for protection from COVID-19. Multiple studies indicate that neutralizing antibodies decline 6 months after natural infection and it is not yet clear if cellular immunity will provide longer protection. Some studies show the more severe the natural COVID-19 infection, the higher the immune response and the longer the protection. During this session, experts will discuss the implications fo emerging variants for natural re-infection, vaccine escape and antibody treatments. They will explain the concept of herd immunity as a key concept of epidemic control and discuss the current understanding of protective COVID-19 immune responses in special populations such as the elderly, children and the obese. There will be time for questions from the audience.

Watch Here

*This webinar is supported by an Unrestricted Educational Grant from Pfizer Global Medical Grants.

Presentado: Dr. Majorie Pollack, USA & Dr. Uzma Bashir Aamir, Pakistan

Moderado por: Dr. Therese Umuhoza, Kenya

Abstract: En la noche del 30 de diciembre de 2019, la Editora Adjunta del Programa de Monitoreo de Enfermedades Emergentes (ProMED) de ISID, la Dra. Marjorie Pollack publicó una solicitud de información a la red ProMED después de ser contactada por un colega de confianza sobre un grupo de casos de neumonía no diagnosticados en Wuhan, China. A través de su experiencia previa con SARS décadas antes, Marjorie sabía que esta nueva amenaza debía tomarse en serio. Afortunadamente sonó la alarma, y al hacerlo fue la primera en proporcionar un informe detallado alertando a la comunidad internacional de enfermedades infecciosas sobre lo que evolucionó en lo que ahora conocemos como la pandemia global de COVID-19. Con su colega, la Dra. Uzma Aamir, este seminario web es una discusión cercana y personal con Marjorie, moderada por la Dra. Therese Umuhoza.

Ver ahora


Prof. Gagandeep Kang, ISID Executive Committee Member, India

  • Global Access

Dr. Heidi Larson, The Vaccine Confidence Project, United Kingdom

  • How Vaccine Rumors Start & Why They Don’t Go Away

Moderator: Prof. Paul Tambyah, ISID President-Elect, Singapore

Abstract: The development of accepted vaccines that are available on a global scale is a priority to end the COVID-19 pandemic. Recently, there have been dramatic shifts in vaccine confidence around the world that threaten the success of approved COVID-19 vaccines as well as the likelihood of achieving herd immunity. This webinar will discuss the current state of COVID-19 vaccine confidence, reasons for hesitancy, and will propose ways forward. The need for COVID-19 vaccines is global, although the need is differentially distributed within populations. High income countries must not monopolize the global supply and every effort must be made to provide vaccines at a price affordable to low- and middle-income countries. Understanding the complexities of establishing a regionally and globally fair vaccine-allocation system are essential.

Watch Here

*This webinar is supported by an Unrestricted Educational Grant from Pfizer Global Medical Grants.

Speaker: Prof. Angela Gentile, University of Buenos Aires, Argentina

Moderators: Prof. Miguel O'Ryan, ISID Executive Committee Member, Chile & Dr. Tatiana Pinto, ISID Emerging Leader, Brazil

Abstract: El desarrollo de vacunas aceptadas que estén disponibles a escala global es una prioridad para finalizar la pandemia de COVID-19. Recientemente, hubo cambios dramáticos en la confianza de la vacuna alrededor del mundo que amenazan el éxito de las vacunas aprobadas contra COVID-19 como así también la probabilidad de lograr inmunidad de rebaño. Este seminario web incluirá una discusión en vivo y Preguntas & Respuestas sobre el estado actual de la confianza de la vacuna contra COVID-19 en América Latina, las razones de la vacilación, y propondrá caminos a seguir.


Ver ahora

Speaker: Prof. Shabir Madhi, University of Witwatersrand, South Africa

Moderator: Prof. Neelika Malavige, ISID Executive Committee Member, Sri Lanka

Abstract: Where are we with delivering safe, efficacious COVID-19 vaccines globally? What are the challenges and opportunities? This webinar provides important updates in the currently approved COVID-19 vaccines and an overview of ongoing Phase 3 trials. Attention will be paid to the vaccination of special groups such as immunocompromised individuals, children and pregnant women. We also discuss the elements required to achieve herd immunity and answer your questions about COVID-19 vaccination!

Watch Here

*This webinar is supported by an Unrestricted Educational Grant from Pfizer Global Medical Grants.

Speakers: Dr. Victor Nizet, University of California San Diego

Moderators: Prof. Marc Mendelson & Dr. Connie Walyaro

Abstract: Before the patient has even seen a doctor, their infection is already being treated by multiple antimicrobials - namely the cellular and molecular components of the innate immune system. Conventional screening paradigms in antibiotic discovery are based on MIC/MBC testing in conventional bacteriologic media, and similar tests on patient isolates are used to guide physician management. Antibiotics can synergize with endogenous antimicrobial peptides to effect bacterial killing. These studies will reveal how standard MIC testing can be misleading, overlooking potent antibiotic activities that are recognized only the context of the normal innate immune system.  In this new discovery and treatment framework, drugs used in medicine for other indications (e.g. cholesterol-lowering or antiplatelet drugs), or antibiotics otherwise deemed ineffective, can be "repositioned" for treatment of multi-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) or carbapenemase-resistant strains of Gram-negative pathogens including Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Watch Here

In Collaboration with EcoHealth Alliance, Featuring:
Dr. Peter Daszak, President, EcoHealth Alliance
"Environmental Change and Emerging Infectious Diseases"

Prof. George Gao, Director-General, Chinese Center for Disease Control and Prevention
"One Health and Pandemic Preparedness in China and Beyond"

Dr. Kanta Kumari Rigaud, Lead Enviromental Specialist & Regional Climate Change Coordinayor - Africa Region, World Bank
"Climate Change, Migration, and Infectious Diseases" 

Moderated by: Dr. Larry Madoff (USA) & Dr. Salma Ferchichi (Tunisia)

Watch Here

With generous support from the Bill & Melinda Gates Foundation, ISID presents research selected for presentation at the 19th International Congress on Infectious Diseases (ICID). This collection of ePosters reflects the contributions of early-career investigators working to advance our understanding of infectious disease challenges in low-resource settings. These studies were selected from over 1,900 abstracts due to their quality and the valuable knowledge they add to the field of infectious diseases. With topics ranging from antimicrobial resistance, disease surveillance, HIV situational assessments, metagenomics, arboviruses, and public health epidemiology, there is something to engage all interests. As you interact with these ePosters, please feel free to leave a comment or question for the researchers.

Check Out the ePosters

Speakers: Dr. Marjorie Pollack (USA) & Dr. Uzma Aamir (Pakistan)

Moderators: Dr. Therese Umuhoza (Kenya)

On the night of December 30, 2019, ISID’s Program for Monitoring Emerging Diseases (ProMED) Deputy Editor, Dr. Marjorie Pollack posted a request for information to the ProMED network after being contacted by a trusted colleague about a cluster of undiagnosed pneumonia cases in Wuhan, China. Through her previous experience with SARS decades earlier, Marjorie knew this new threat must be taken seriously. Luckily she sounded the alarm, and in doing so was the first to provide a detailed report alerting the international infectious diseases community to what evolved into what we now know as the global COVID-19 pandemic. With her colleague, Dr. Uzma Aamir, this webinar is an up-close and personal discussion with Marjorie, moderated by Dr. Therese Umuhoza.

Watch Here

Speakers: Prof. Lulu Bravo (The Philippines) & Prof. Francois Venter (South Africa)

Moderators: Prof. Alison Holmes (United Kingdom), Prof. Paul Tambyah (Singapore), Dr. Afreenish Amir (Pakistan)

Abstract: COVID-19 may have complex short- and long-term effects on global infectious disease priorities. With the world’s attention and resources focused towards COVID-19 prevention and response efforts, we are at risk of major infectious diseases making a comeback. As observed during previous crises, the indirect morbidity and mortality effects of the ongoing COVID-19 pandemic may be as important as the direct effects of the pandemic itself. There are widespread disruptions to HIV, TB and malaria service delivery programs globally with shortages in medical supplies, treatments and diagnostics. Existing programs have been hit by lockdowns, changing funding priorities and re-allocation of staff and resources. It is estimated that the disruption of routine childhood immunization services across the globe puts at least 80 million children under one at risk of vaccine-preventable diseases such as measles, mumps, rubella, polio, yellow fever, typhoid, cholera and tetanus. On the other hand, emphasis on infection prevention measures such as hand hygiene and social distancing could reduce the occurrence of community and healthcare associated infectious diseases, providing an opportunity to harness improved practices, behavior changes and attitude modifications relevant to the management of many infections. The full impact of COVID-19 on respiratory diseases and the influenza season remains unknown. Disruptions in disease surveillance and reporting further add to the complexity of understanding the true impact of COVID-19 on communicable diseases.

Watch Here

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

IKEEP Scientific Committee

Read more about ISID's governance.

Prof. Alison Holmes
Imperial College London, UK

Prof. Alison Holmes
Imperial College London, UK
Conflict of Interest

Paul Tambyah

Prof. Paul Tambyah
National University of Singapore, Singapore
Conflict of Interest

Marc Mendelson

Prof. Marc Mendelson
University of Cape Town, South Africa
Conflict of Interest

Sally Roberts

Prof. Sally Roberts
University of Auckland, School of Medicine, New Zealand
Conflict of Interest

Robert Heyderman

Prof. Robert Heyderman
NIHR Global Health Research Unit on Mucosal Pathogens
London, UK
Conflict of Interest

Gagandeep Kang

Prof. Gagandeep Kang
Translational Health Service and Technology Institute
Conflict of Interest

Neelika Malavige

Prof. Gathsaurie Malavige
University of Sri Jayewardenepura
Sri Lanka
Conflict of Interest

Miguel O'Ryan

Prof. Miguel O'Ryan
Faculty of Medicine, University of Chile
Santiago, Chile
Conflict of Interest

Zamberi Sekawi

Prof. Zamberi Sekawi
Universiti Putra Malaysia
Kuala Lumpur, Malaysia
Conflict of Interest

Ursula Theuretzbacher

Prof. Ursula Theuretzbacher
Center of Anti-Infective Agents
Vienna, Austria
Conflict of Interest

Britta Lassmann

Dr. Britta Lassmann
International Society for Infectious Diseases
Boston, USA
Conflict of Interest

For sponsorship opportunities please reach out to Catherine Crowley ([email protected])